The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic neisseria meningitidis serogroups a, c, y, w135. [description]the vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of neisseria meningitidis group acyw135 respectively and iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying phosphate buffered saline (pbs) immediately, and turn into a clear liquid after reconstitution.active constituent: neisseria meningitidis group acyw135 capsular polysaccharides.subsidiary materials: all the components of subsidiary materials approved shall be listed.vaccine diluent: sterile, pyrogen-free pbs.[specifications]0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing 200g of meningococcal polysaccharide (50g of each polysaccharide of group a, c, y, w135). [contraindications](1) subjects with known allergic reactions to any component of the vaccine.(2) subjects with acute diseases, severe chronic diseases, chronic diseases at stage of acute attack or fever.(3) subjects with encephalopathy, uncontrolled epilepsy, and other progressive diseases of nervous system.[precautions](1) the vaccine should be administered with caution to the subjects with family or individual history of convulsion or those with chronic diseases, history of epilepsy, allergic diathesis or www.ccls-vaccine.com
Changchun, China
Write a Review
Amy Yuan (ChangchunChangshengLifeSciencesLtd.)
Share us via
